Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系

doi:10.11904/j.issn.1002-3070.2016.02.001

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (2): 97-102.doi: 10.11904/j.issn.1002-3070.2016.02.001

• 论著 • 下一篇

Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系

叶磊光, 闫安, 刘宝刚

哈尔滨医科大学附属肿瘤医院内一科(哈尔滨 150040)

收稿日期:2016-02-17 出版日期:2016-04-28 发布日期:2016-04-28
通讯作者: 刘宝刚,E-mail:liubaogang1962@sina.com
作者简介:叶磊光,女,(1981-),硕士,主治医师,从事非小细胞肺癌侵袭和转移的研究
基金资助:
黑龙江省自然科学基金项目(D201238)

Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer

YE Leiguang, YAN An, LIU Baogang

Department of Oncology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150040,China

Received:2016-02-17 Online:2016-04-28 Published:2016-04-28

摘要/Abstract

摘要： 目的本研究旨在探索Aurora-A在非小细胞肺癌(Non-small cell lung cancer,NSCLC)的表达情况,以及其与化疗药耐药性和预后的关系。方法选取哈尔滨医科大学附属肿瘤医院,2010年5月—2013年10月收治的NSCLC患者纳入本次研究,共62例。所有患者均接受手术治疗,手术后接受顺铂为基础的化疗。制作组织芯片,Aurora-A在NSCLC组织的表达情况用免疫组化的方法进行检测,Aurora-A与临床指标的关系进行相关分析,采用Kaplan-Meier单因素生存分析的方法进行总生存率的分析,应用Log-rank检验Aurora-A高表达组与低表达组之间的差异性。结果免疫组化检测结果显示,在62例患者中,26例患者为Aurora-A高表达。高表达组和低表达组两组患者年龄、性别构成比、TNM分期等差异均无统计学意义。高表达组中位生存时间为50.1个月,而低表达组中位生存时间为55.8个月,两组差异有统计学意义(P=0.047)。结论对于接受顺铂为基础的化疗的NSCLC患者,Aurora-A的高表达与不良预后相关。Aurora-A有望成为治疗NSCLC耐药性的新靶点。

关键词: Aurora-A, 非小细胞肺癌, 预后

Abstract: Objective To identify the expression of Aurora-A and its correlation with cisplatin resistance and prognosis in non-small cell lung cancer(NSCLC).Methods A total of 62 NSCLC patients treated by surgery and adjuvant cisplatin-based chemotherapy were included in our study.The expression of Aurora-A was determined by immunohistochemical(IHC)analysis.Correlation between Aurora-A expression and clinic pathological variables was estimated.The prognostic significances were assessed by Kaplan-Meier method,and the differences in survival probabilities were evaluated by the Log-rank test.Results IHC showed that 26 out of the 62 NSCLC patients were with high Aurora-A.There was no significant association between Aurora-A expression and clinic pathological variables.The overall survival of patients with high Aurora-A expression(median survival time:50.1 months)was significantly poorer than those with low Aurora-A expression(median survival time:55.8 months).Conclusion The present study suggests that high Aurora-A expression is correlated with cisplatin-based chemotherapeutic resistance and predicts poor patient survival in NSCLC.However,further in vitro study is needed.

Key words: Aurora-A, Non-small cell lung cancer, Prognosis

中图分类号:

R734.2

叶磊光, 闫安, 刘宝刚. Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系[J]. 实用肿瘤学杂志, 2016, 30(2): 97-102.

YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.

参考文献

1 Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
2 任玲,夏媛,操乐杰.长春瑞滨联用顺铂与吉西他滨联用顺铂治疗晚期非小细胞肺癌的临床观察[J].中国临床保健杂志,2010,13(2):124-126.
3 Nadkar A,Pungaliya C,Drake K,et al.Therapeutic resistance in lung cancer[J].Expert Opin Drug Metab Toxicol,2006,2(5):753-777.
4 Marumoto T,Zhang D,Saya H.Aurora-A-a guardian of poles[J].Nat Rev Cancer,2005,5(1):42-50.
5 Yang H,He L,Kruk P,et al.Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells[J].Int J Cancer,2006,119(10):2304-2312.
6 Wang LH,Xiang J,Yan M,et al.The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway[J].Cancer Res,2010,70(22):9118-9128.
7 冯蕾,慕博华,饶秋,等.FOXC1在非小细胞肺癌组织中的表达及预后意义[J].南京医科大学学报:自然科学版,2013,33(12):1693-1697.
8 Gritsko TM,Coppola D,Paciga JE,et al.Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer[J].Clin Cancer Res,2003,9(4):1420-1426.
9 Li D,Zhu J,Firozi PF,et al.Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer[J].Clin Cancer Res,2003,9(3):991-997.
10 张志宏,刘志礼,罗庆丰,等.Aurora-A激酶在骨肉瘤中的表达及意义[J].广东医学,2013,34(10):1562-1564.
11 Lassus H,Staff S,Leminen A.Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma[J].Gynecol Oncol,2011,120(1):11-17.
12 Cammareri P,Scopelliti A,Todaro M,et al.Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells[J].Cancer Res,2010,70(11):4655-4665.
13 Scharer CD,Laycock N,Osunkoya AO,et al.Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells[J].J Transl Med,2008,6(79):1186-1479.
14 Sun C,Chan F,Briassouli P,et al.Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents[J].Biochem Biophys Res Commun,2007,352(1):220-225.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[3]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[4]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[5]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[6]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[7]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[8]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[9]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[10]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[14]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[15]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.

Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系

Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价